Literature DB >> 9851782

Activating mutations of the Gs alpha gene are associated with low levels of Gs alpha protein in growth hormone-secreting tumors.

E Ballaré1, S Mantovani, A Lania, A M Di Blasio, L Vallar, A Spada.   

Abstract

Evidence suggests the existence of a direct relationship between cellular Gs alpha content and activation of the adenylyl cyclase system. Data on Gs alpha levels in endocrine tumors that depend on cAMP for growth, particularly pituitary adenomas, are still limited. The levels of Gs alpha protein were evaluated in 11 GH-secreting adenomas with Gs alpha mutations (gsp+) and 15 without (gsp). Complementary DNAs from gsp+ tumors contained very low amounts of wild-type Gs alpha sequences, indicating a preponderance of the mutant Gs alpha transcripts in these tumors. Immunoblotting of Gs alpha protein showed that the two isoforms were present at high levels in all gsp-, but were undetectable or barely detectable in gsp+. The low Gs alpha content in gsp+ tumors was not due to a reduction in ribonucleic acid synthesis or stability, as Gs alpha messenger ribonucleic acid levels were similar in wild-type and mutant tissues. Treatment of gsp- cells with cholera toxin caused a marked reduction of Gs alpha levels. As in other cell systems cholera toxin increases Gs alpha degradation, our data are consistent with an accelerated removal of mutant Gs alpha. This may represent an additional mechanism of feedback response to the constitutive activation of cAMP signaling in pituitary tumors with mutations in the Gs alpha gene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851782     DOI: 10.1210/jcem.83.12.5354

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Expression of potassium channel isoforms mRNA in normal human adrenals and aldosterone-secreting adenomas.

Authors:  R Sarzani; F Pietrucci; M Francioni; F Salvi; C Letizia; E D'Erasmo; P Dessì Fulgheri; A Rappelli
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

2.  Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas.

Authors:  M Filopanti; E Ballarè; A G Lania; S Bondioni; U Verga; M Locatelli; L M Zavanone; M Losa; S Gelmini; A Peri; C Orlando; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

3.  Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly.

Authors:  B E Hayward; A Barlier; M Korbonits; A B Grossman; P Jacquet; A Enjalbert; D T Bonthron
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 4.  Genesis of pituitary adenomas: state of the art.

Authors:  G Faglia; A Spada
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

5.  Gonadotropin-releasing hormone initiates multiple signaling pathways in human GH-secreting adenomas.

Authors:  A Lania; G Mantovani; E Ferrante; L M Zavanone; M Locatelli; S Corbetta; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

6.  G protein mutations in pituitary tumors: a study on Turkish patients.

Authors:  Beki Kan; Christopher Esapa; Tammam Sipahi; Cevdet Nacar; Fahir Ozer; Nur Buyru Sayhan; Mehmet Yaşar Kaynar; Ali Cetin Sarioğlu; Philip Edward Harris
Journal:  Pituitary       Date:  2003-09       Impact factor: 4.107

7.  Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience.

Authors:  Giselle Fernandes Taboada; Ana Lúcia Osório Tabet; Luciana A Naves; Denise Pires de Carvalho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

8.  Neonatal McCune-Albright Syndrome: A Unique Syndromic Profile With an Unfavorable Outcome.

Authors:  Alessandro Corsi; Natasha Cherman; David L Donaldson; Pamela G Robey; Michael T Collins; Mara Riminucci
Journal:  JBMR Plus       Date:  2019-01-15

9.  The curious case of Gαs gain-of-function in neoplasia.

Authors:  Giulio Innamorati; Thomas M Wilkie; Havish S Kantheti; Maria Teresa Valenti; Luca Dalle Carbonare; Luca Giacomello; Marco Parenti; Davide Melisi; Claudio Bassi
Journal:  BMC Cancer       Date:  2018-03-15       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.